- Wednesday, July 2, 2025 @ 12:00 am
RDP Pharma AG, a biotechnology company focused on next-generation protein degradation therapeutics, today announced a strategic research collaboration with the Experimental Drug Development Centre (EDDC), Singapore’s national platform for drug discovery and development, to jointly discover and develop a monovalent targeted protein degrader for anti-inflammatory therapies.
The collaboration brings together RDP Pharma’s expertise in rational protein degrader design and EDDC’s integrated drug discovery and development capabilities, to address a classically undruggable target known to play a key role in activating the inflammatory response pathway. The partners aim to advance a novel, orally available therapeutic for inflammation-driven autoimmune diseases.
“This collaboration leverages the unique strengths of both organizations. Our platform enables rational design of precision degraders against hard-to-drug targets, and EDDC’s deep expertise in target biology and translational research provides the ideal framework to accelerate development. Together, we aim to unlock new therapeutic avenues in inflammatory diseases where current treatments fall short.” said Markus Muellner, Chief Technology Officer of RDP Pharma AG.
“We are excited to embark on this partnership with RDP Pharma, continuing our goal of expanding capabilities in the development of monovalent small molecule degraders. Our expertise in drug discovery and development, coupled with RDP Pharma’s protein degrader platform, allows us to explore new approaches to previously undruggable targets. We look forward to advancing this program together and creating a transformative impact for patients with chronic inflammatory and autoimmune diseases,” said Prof Damian O’Connell, Chief Executive Officer of EDDC.”
